Rodman & Renshaw initiated coverage of Rockwell Medical (RMTI) with a Buy rating and $5 price target Rockwell has been a leading provider of dialysis concentrates in the U.S. for over 20 years, supplying essential concentrates used in dialysis machines to help patients with kidney issues, the analyst tells investors in a research note. The firm says that with expected revenue of over $65M in 2025 and potential for further gross margin improvement, the company remains undervalued despite the challenges of heavy customer concentration risk.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMTI:
- Rockwell Medical Reports Strong Q3 2024 Earnings
- Rockwell Med Reveals Strategic Corporate Presentation
- Rockwell Medical raises 2024 revenue view to $98.0M-$101.0M from $95.0M-$98.0M
- Rockwell Medical reports Q3 adjusted EPS 9c vs. (4c)
- Options Volatility and Implied Earnings Moves Today, November 11, 2024